ClinicalTrials.gg

Program

Pneumococcal 21-Valent Conjugate Vaccine

Also written as “V116”, “PCV21 vaccine” and “PCV21”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Anemia, Sickle Cell, led by 2 companies.

Furthest: phase 3, since May 23, 202218 company-led studies, 7 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck110 open or runningphase 3since May 23, 2022Nov 18, 2019none ahead
Sanofi77 open or runningphase 3since Oct 10, 2024Oct 10, 2024Dec 1, 2026phase 3 · NCT06838000

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 18, 2019.

  1. May 23, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05393037 · 313 enrolled · United States, Belgium, Chile and more
  2. Jun 13, 20222 phase 3 studiesMerck · NCT05420961, NCT05425732
  3. Jul 12, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05464420 · 2,162 enrolled · United States, Austria, Canada and more
  4. Aug 31, 2022Phase 3 study in Pneumonia, PneumococcalMerck · NCT05526716 · 1,080 enrolled · United States
  5. Oct 4, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05569954 · 1,484 enrolled · Argentina, Australia, Colombia and more
  6. Nov 21, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05633992 · 450 enrolled · Japan
  7. Jan 13, 2023Phase 3 study in Pneumococcal InfectionsMerck · NCT05696080 · 518 enrolled · United States, Australia, Canada and more
  8. Dec 11, 2023Phase 3 study in Pneumococcal InfectionsMerck · NCT06177912 · 882 enrolled · United States, Canada, Chile and more
  9. Oct 10, 2024Sanofi’s first study: phase 3 study in Pneumococcal InfectionsNew to SanofiSanofi · NCT06838000 · 1,268 enrolled · United States, Estonia, Poland and more
  10. Dec 11, 2024Phase 3 study in Pneumococcal ImmunizationSanofi · NCT06736041 · 1,714 enrolled · United States, Australia, Honduras and more
  11. Feb 7, 20252 phase 3 studies in Pneumococcal ImmunizationSanofi · NCT06824194, NCT06824181
  12. May 8, 2025Phase 3 study in Pneumococcal ImmunizationSanofi · NCT06975878 · 1,092 enrolled · Belgium, Czechia, Estonia and more
  13. Nov 19, 2025Phase 3 study in Anemia, Sickle CellSanofi · NCT07247188 · 100 planned · United States, Dominican Republic
  14. Jan 15, 2026Phase 3 study in Pneumococcal InfectionsSanofi · NCT07348692 · 2,195 planned · United States, Honduras, Puerto Rico and more

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Pneumococcal InfectionsSanofi · NCT06838000
  2. Jan 7, 2027Primary completion: phase 3 study in Anemia, Sickle CellSanofi · NCT07247188
  3. May 17, 2027Primary completion: phase 3 study in Pneumococcal ImmunizationSanofi · NCT06736041
  4. Jun 7, 2027Primary completion: phase 3 study in Pneumococcal InfectionsSanofi · NCT07348692

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 21 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 21-Valent Conjugate Vaccine”name, by rule

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07348692Pneumococcal Infections · United States, Honduras, Puerto Rico and more3RecruitingSanofiJun 7, 20272,195
NCT07247188Anemia, Sickle Cell · United States, Dominican Republic3RecruitingSanofiJan 7, 2027100
NCT06975878Pneumococcal Immunization · Belgium, Czechia, Estonia and more3Active, not recruitingSanofiAug 25, 20271,092
NCT06824194Pneumococcal Immunization · United States, Honduras, Mexico and more3Active, not recruitingSanofiOct 22, 20272,360
NCT06824181Pneumococcal Immunization · United States, Chile, Mexico and more3Active, not recruitingSanofiSep 10, 2027580
NCT06736041Pneumococcal Immunization · United States, Australia, Honduras and more3Active, not recruitingSanofiMay 17, 20271,714
NCT06838000Pneumococcal Infections · United States, Estonia, Poland and more3Active, not recruitingSanofiDec 1, 20261,268
NCT06177912Pneumococcal Infections · United States, Canada, Chile and more3CompletedMerckFeb 26, 2025882
NCT05696080Pneumococcal Infections · United States, Australia, Canada and more3CompletedMerckFeb 16, 2024518
NCT05633992Pneumococcal Infections · Japan3CompletedMerckMay 24, 2023450
NCT05569954Pneumococcal Infections · Argentina, Australia, Colombia and more3CompletedMerckOct 30, 20231,484
NCT05526716Pneumonia, Pneumococcal · United States3CompletedMerckJun 21, 20231,080
NCT05464420Pneumococcal Infections · United States, Austria, Canada and more3CompletedMerckMay 25, 20232,162
NCT05425732Pneumococcal Infections · United States, Australia, Belgium and more3CompletedMerckMay 18, 20232,663
NCT05420961Pneumonia, Pneumococcal · United States, Canada, France and more3CompletedMerckMay 16, 2023717
NCT05393037Pneumococcal Infections · United States, Belgium, Chile and more3CompletedMerckJul 13, 2023313
NCT04665050Pneumococcal Infections · Japan1CompletedMerckApr 6, 2021102
NCT04168190Pneumonia, Pneumococcal · United States2CompletedMerckJul 12, 2021600

How it is read

Names in the registry

  • “V116”, 11 entries
  • “PCV21 vaccine”, 5 entries
  • “PCV21”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.